Abivax S.A.
Business
Abivax SA is a clinical-stage biotechnology company developing obefazimod, an oral small-molecule drug candidate targeting inflammatory bowel diseases, primarily ulcerative colitis and Crohn's disease. Obefazimod enhances expression of miR-124, a micro-RNA that regulates inflammatory response, with Phase 3 induction trials completed and maintenance data expected in late second quarter 2026. The company is also evaluating combination therapy opportunities and expanding its pipeline with follow-on miR-124 platform compounds. Abivax conducts clinical trials across North America, Latin America, Europe and Asia Pacific, with regulatory submissions anticipated in the United States and European Union.
Summary from 20-F filed 2026-03-23
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-336.10M |
| Total assets | $584.34M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Abivax S.A.'s CIK number?
Abivax S.A.'s SEC CIK number is 0001956827 (1956827). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Abivax S.A.'s SEC filings?
All of Abivax S.A.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.